Comparative Pharmacology
Head-to-head clinical analysis: FLUVASTATIN SODIUM versus ZYPITAMAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUVASTATIN SODIUM versus ZYPITAMAG.
FLUVASTATIN SODIUM vs ZYPITAMAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to decreased intracellular cholesterol levels and upregulation of LDL receptors.
ZYPITAMAG (pitavastatin magnesium) is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, leading to reduced intracellular cholesterol and upregulation of LDL receptors.
20 to 80 mg orally once daily in the evening; immediate-release: 20-40 mg once daily; extended-release: 80 mg once daily.
2-4 mg orally once daily, at any time of day, with or without food.
None Documented
None Documented
The terminal elimination half-life is 2.3 hours (range 1.4–3.1 hours). Due to its short half-life, it is dosed once daily for sustained HMG-CoA reductase inhibition; however, pharmacodynamic effects (LDL reduction) persist beyond plasma clearance.
Terminal elimination half-life: 12 hours (range 10-14 h) in healthy subjects; supports once-daily dosing
Fluvastatin sodium is primarily eliminated via biliary/fecal excretion (approximately 90%), with renal excretion accounting for less than 6% of the administered dose.
Primarily renal (93% as unchanged pitavastatin and metabolites) via active tubular secretion; fecal (5%)
Category D/X
Category C
Statin
Statin